Fedele S, Fung P P L, Bamashmous N, Petrie A, Porter S
University College London/University College London Hospital, Eastman Dental Institute and Hospital, Oral Medicine Unit, 256 Gray's Inn Road, London, WC1X 8LD, U.K; NIHR Biomedical Research Centre at University College London Hospital NHS Foundation Trust and University College London, Maple House Suite A 1st floor, 149 Tottenham Court Road, London, W1T 7DN, U.K.
Br J Dermatol. 2014 Apr;170(4):794-801. doi: 10.1111/bjd.12655.
It has been suggested that intralesional triamcinolone injections represent a safe and effective therapeutic strategy in controlling the permanent disfiguring swelling of orofacial granulomatosis (OFG). However, robust supporting evidence is lacking, due to the variable and inconsistent design of available studies.
To investigate whether a standardized regimen of intralesional triamcinolone has beneficial long-term effects on orofacial swelling of OFG. We also studied potential associations with a number of prognostic factors.
We designed a retrospective observational study of a homogeneous cohort of 22 well-phenotyped patients with OFG. The primary outcome was defined as a statistically significant decrease in post-treatment disease severity. Statistically significant association with prognostic factors was the secondary outcome. Statistical analysis included Wilcoxon signed-rank tests and logistic regression.
Compared with pretreatment, there were statistically significant decreases in disease severity scores at all time points until 48 months post-treatment (P < 0·01). Logistic regression analysis showed there was no independent prognostic variable of statistical significance (P > 0·05). The majority of patients (14/22, 63·6%) received one course of intralesional triamcinolone and did not experience disease recurrence. The mean disease-free period after the first course of intralesional therapy was 28·9 ± 18 months (95% confidence interval 28·7-29·1). No adverse effects were reported.
This is the first study to have employed robust cohort methodology and sound statistics to demonstrate long-term effectiveness of intralesional triamcinolone in controlling the disfiguring swelling of OFG. Because of limitations inherent in observational studies, further research in the form of randomized case-control trials is needed to confirm the present findings.
有人提出,病灶内注射曲安奈德是控制口面部肉芽肿病(OFG)永久性毁容性肿胀的一种安全有效的治疗策略。然而,由于现有研究设计的多样性和不一致性,缺乏有力的支持证据。
研究病灶内注射曲安奈德的标准化方案对OFG口面部肿胀是否具有长期有益效果。我们还研究了与一些预后因素的潜在关联。
我们对22例表型明确的OFG患者进行了一项回顾性观察研究。主要结局定义为治疗后疾病严重程度有统计学意义的降低。与预后因素的统计学显著关联为次要结局。统计分析包括Wilcoxon符号秩检验和逻辑回归。
与治疗前相比,直到治疗后48个月的所有时间点,疾病严重程度评分均有统计学意义的下降(P < 0·01)。逻辑回归分析显示,没有具有统计学意义的独立预后变量(P > 0·05)。大多数患者(14/22,63·6%)接受了一个疗程的病灶内曲安奈德注射,且未出现疾病复发。病灶内治疗第一个疗程后的平均无病期为28·9 ± 18个月(95%置信区间28·7 - 29·1)。未报告不良反应。
这是第一项采用可靠队列方法和合理统计数据来证明病灶内注射曲安奈德在控制OFG毁容性肿胀方面长期有效性的研究。由于观察性研究固有的局限性,需要以随机病例对照试验的形式进行进一步研究来证实目前的发现。